Glaxosmithkline Pharmaceuticals Ltd Half Yearly Results

Gross Sales

1,923.79

1,825.42

1,735.06

1,718.65

1,589.75

Excise Duty

0

0

0

0

0

Net Sales

1,923.79

1,825.42

1,735.06

1,718.65

1,589.75

Other Operating Income

0

0

0

0

0

Other Income

75.75

74.87

40.64

81.95

51.08

Total Income

1,999.54

1,900.29

1,775.7

1,800.6

1,640.83

Total Expenditure

1,298.68

1,273.17

1,403.35

1,285.28

1,192.28

PBIDT

700.86

627.12

372.35

515.32

448.55

Interest

0.67

0.64

1.09

0.71

0.74

PBDT

700.19

626.48

371.26

514.61

447.81

Depreciation

33.52

33.27

35.21

34.47

33.59

Minority Interest Before NP

0

0

0

0

0

Tax

163.64

162.32

93.08

144.51

126.5

Deferred Tax

10.28

-3.94

2.77

-14.13

-10.27

Reported Profit After Tax

492.75

434.83

240.2

349.76

297.99

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

492.75

434.83

240.2

349.76

297.99

Extra-ordinary Items

0

3.41

-160.91

12.09

-0.97

Adjusted Profit After Extra-ordinary item

492.75

431.42

401.11

337.67

298.96

EPS (Unit Curr.)

29.09

25.43

14.18

19.88

17.59

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

120

0

320

0

Equity

169.41

169.41

169.41

169.41

169.41

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

36.43

34.35

21.46

29.98

28.21

PBDTM(%)

-

-

-

-

-

PATM(%)

25.61

23.82

13.84

20.35

18.74